Table 2. Prevalence of sarcopenia and pre-sarcopenia in T2DM patients and controls, overall and stratified by gender, n (%).
| T2DM patients | Controls | P value** | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall (n = 236) | Men (n = 116) | Women (n = 120) | P value* | Overall (n = 854) | Men (n = 404) | Women (n = 450) | P value* | ||
| Sarcopenia | 35 (14.8) | 20 (17.2) | 15 (12.5) | 0.104 | 96 (11.2) | 53 (13.1) | 43(9.6) | 0.1 | 0.035 |
| Pre-sarcopenia | 34 (14.4) | 22 (19.0) | 12 (10.0) | 0.03 | 72 (8.4) | 46 (11.4) | 26(5.8) | 0.002 | 0.002 |
Sarcopenia is defined as low skeletal muscle index (SMI) (less than 7.0 kg/m2 in men and 5.7 kg/m2 in women) and low muscle strength (handgrip strength <26 kg in men and <18 kg in women) or low physical performance(gait speed <0.8 m/s). Pre-sarcopenia is defined as low SMI but with normal muscle strength and normal physical performance. *Analyzed by chi-square test, compared within gender; **Comparing overall prevalence between patients and controls.